title: Management of Stage I Nonseminomatous Germ Cell Tumors.
abstract: Testis cancer represents the model for a curable malignancy. Although there is consensus about the appropriate management of metastatic (clinical stage [CS] IIC-III) nonseminomatous germ cell tumor (NSGCT) in terms of the chemotherapy regimens, number of cycles, and the surgical resection of postchemotherapy residual masses, there remains controversy regarding the appropriate management of low-stage NSGCT (CSI-IIB). In this article, the benefits and drawbacks of each treatment option are reviewed; an evidence-based approach when confronted with such a patient and how to best select a treatment avenue based on the patient's clinical and pathologic features are also discussed.
authors.affiliation: Glickman Urological & Kidney Institute, Cleveland Clinic, Mail Code Q10-1, 9500 Euclid Avenue, Cleveland Clinic, Cleveland, OH 44195, USA.
authors.forename: Evan
authors.initials: E
authors.lastname: Kovac
authors.affiliation: Center for Urologic Oncology, Glickman Urological & Kidney Institute, Cleveland Clinic, Cleveland Clinic Main Campus, Mail Code Q10-1, 9500 Euclid Avenue, Cleveland, OH 44195, USA. Electronic address: stephea2@ccf.org.
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Stephenson
mesh_terms: D017024:Chemotherapy, Adjuvant / Q000379:methods*; D019468:Disease Management; D006801:Humans; D008197:Lymph Node Excision / Q000379:methods*; D008207:Lymphatic Metastasis; D008297:Male; D009367:Neoplasm Staging; D009373:Neoplasms, Germ Cell and Embryonal / Q000473:pathology / Q000628:therapy; D011379:Prognosis; D012187:Retroperitoneal Space / Q000473:pathology*; D018570:Risk Assessment; D013736:Testicular Neoplasms / Q000473:pathology / Q000628:therapy
keywords: Chemotherapy; Germ cell and embryonal; Lymph node excision; Neoplasm staging; Neoplasms; Retroperitoneum; Surveillance; Testicular neoplasms